Shares of Albany Molecular Research Inc. (NASDAQ:AMRI) traded down 5.1% during mid-day trading on Tuesday . The company traded as low as $13.97 and last traded at $13.97, with a volume of 88,665 shares changing hands. The stock had previously closed at $14.72.

Separately, Morgan Stanley restated a “buy” rating on shares of Albany Molecular Research in a report on Sunday, May 8th.

The stock’s market capitalization is $527.91 million. The stock has a 50 day moving average of $14.02 and a 200 day moving average of $14.76.

Albany Molecular Research (NASDAQ:AMRI) last announced its earnings results on Thursday, August 4th. The company reported $0.36 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.32 by $0.04. The business had revenue of $116.50 million for the quarter, compared to analyst estimates of $123.10 million. Equities research analysts predict that Albany Molecular Research Inc. will post $1.05 EPS for the current year.

In other Albany Molecular Research news, CEO William S. Marth bought 12,500 shares of the firm’s stock in a transaction on Monday, May 16th. The shares were purchased at an average price of $12.86 per share, for a total transaction of $160,750.00. Following the transaction, the chief executive officer now directly owns 524,143 shares in the company, valued at approximately $6,740,478.98. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, SVP Steven R. Hagen sold 2,361 shares of the stock in a transaction that occurred on Friday, May 13th. The stock was sold at an average price of $12.77, for a total transaction of $30,149.97. Following the transaction, the senior vice president now owns 37,564 shares in the company, valued at approximately $479,692.28. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Albany Molecular Research stock. Mutual of America Capital Management LLC raised its position in Albany Molecular Research Inc. (NASDAQ:AMRI) by 5.8% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 158,399 shares of the company’s stock after buying an additional 8,689 shares during the period. Mutual of America Capital Management LLC owned approximately 0.46% of Albany Molecular Research worth $3,144,000 at the end of the most recent quarter.

Albany Molecular Research, Inc is a global contract research and manufacturing company. The Company provides drug discovery, development, and manufacturing services. The Company operates through three segments: Discovery and Development Services (DDS), Active Pharmaceutical Ingredients (API) and Drug Product Manufacturing (DPM).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.